Department of Pharmacology, School of Basic Medical Sciences, Open and Key Laboratory for Pharmacogenomics at Henan Universities (Y.Y., J.W., Z.X., A.D., Y.W., S.H., P.W., L.Z.) and Precision Medicine Center, Academy of Medical Sciences (X.W.), Zhengzhou University, Zhengzhou, China; and Department of Clinical Pharmacology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China (Y.W.).
Department of Pharmacology, School of Basic Medical Sciences, Open and Key Laboratory for Pharmacogenomics at Henan Universities (Y.Y., J.W., Z.X., A.D., Y.W., S.H., P.W., L.Z.) and Precision Medicine Center, Academy of Medical Sciences (X.W.), Zhengzhou University, Zhengzhou, China; and Department of Clinical Pharmacology, School of Medicine, Henan University of Chinese Medicine, Zhengzhou, China (Y.W.)
Drug Metab Dispos. 2024 Sep 16;52(10):1104-1114. doi: 10.1124/dmd.124.001832.
Interindividual variations in the expression and activity of cytochrome P450 enzymes (CYPs) led to lower therapeutic efficacy or adverse drug events. We previously demonstrated that CYPs are regulated by the long noncoding RNAs (lncRNAs) hepatocyte nuclear factor 1a antisense RNA 1 (HNF1A-AS1) and HNF4A-AS1 via transcription factors (TFs) including hepatocyte nuclear factor 1a (HNF1A), hepatocyte nuclear factor 4a (HNF4A), and pregnane X receptor (PXR). However, the upstream mechanisms regulating HNF1A-AS1 and HNF4A-AS1 are poorly understood. N6-methyladenosine (m6A) is a prevalent epitranscriptomic modification in mammalian RNA. Therefore, the aim of this study was to investigate whether m6A modification regulates the expression of HNF1A-AS1 and HNF4A-AS1 and affects CYP expression in HepG2 and Huh7 cells. The methyltransferase-like 3 (METTL3) inhibitor, STM2457, significantly suppressed the expression of HNF1A-AS1 and induced HNF4A-AS1 expression. Consistent with this, a loss-of-function assay of METTL3 in the cell lines resulted in the downregulation of HNF1A-AS1 and its downstream HNF1A, PXR, and CYPs at the RNA level, as well as the downregulation of some CYPs proteins, and upregulation of HNF4A-AS1. The results of gain-of-function experiments showed the opposite trend. Mechanistically, subsequent RNA stability experiments confirmed that METTL3 affected the stability of both lncRNAs, but in opposite ways; that is, METTL3 reduced HNF1A-AS1 stability and increased HNF4A-AS1 stability. Rescue experiments confirmed that the regulation of METTL3 on TFs and CYPs may require the involvement of these two lncRNAs. Altogether, our study demonstrates that METTL3 is involved in TFs-mediated CYP expression by affecting HNF1A-AS1/HNF4A-AS1 stability. SIGNIFICANCE STATEMENT: Although the impact of long noncoding RNAs (lncRNAs) including hepatocyte nuclear factor 1a antisense RNA 1 (HNF1A-AS1) and hepatocyte nuclear factor 4a antisense RNA 1 (HNF4A-AS1) on the downstream transcription factor (TF) and cytochrome P450 enzyme (CYP) expression is well studied, the upstream regulation of these two lncRNAs by methyltransferase-like 3 (METTL3) remains unexplored. This study reveals that METTL3 is involved in the regulation of lncRNA-TF-CYP expression by affecting the stability of HNF1A-AS1 and HNF4A-AS1 in HepG2 and Huh7 cells.
个体间细胞色素 P450 酶 (CYPs) 的表达和活性存在差异,导致治疗效果降低或药物不良反应。我们之前的研究表明,长链非编码 RNA (lncRNA) 肝细胞核因子 1a 反义 RNA 1 (HNF1A-AS1) 和 HNF4A-AS1 通过转录因子 (TF) 调节 CYPs,包括肝细胞核因子 1a (HNF1A)、肝细胞核因子 4a (HNF4A) 和孕烷 X 受体 (PXR)。然而,调节 HNF1A-AS1 和 HNF4A-AS1 的上游机制尚不清楚。N6-甲基腺苷 (m6A) 是哺乳动物 RNA 中一种普遍的转录后修饰。因此,本研究旨在探讨 m6A 修饰是否调节 HNF1A-AS1 和 HNF4A-AS1 的表达,并影响 HepG2 和 Huh7 细胞中的 CYP 表达。甲基转移酶样 3 (METTL3) 抑制剂 STM2457 显著抑制 HNF1A-AS1 的表达,并诱导 HNF4A-AS1 的表达。与此一致,细胞系中 METTL3 的功能丧失实验导致 HNF1A-AS1 及其下游 HNF1A、PXR 和 CYP 在 RNA 水平下调,以及一些 CYP 蛋白下调,HNF4A-AS1 上调。功能获得实验的结果显示出相反的趋势。机制研究表明,随后的 RNA 稳定性实验证实 METTL3 以相反的方式影响这两种 lncRNA 的稳定性;也就是说,METTL3 降低 HNF1A-AS1 的稳定性并增加 HNF4A-AS1 的稳定性。挽救实验证实,METTL3 对 TF 和 CYP 的调节可能需要这两种 lncRNA 的参与。总之,我们的研究表明,METTL3 通过影响 HNF1A-AS1/HNF4A-AS1 的稳定性,参与 TF 介导的 CYP 表达。
尽管包括肝细胞核因子 1a 反义 RNA 1 (HNF1A-AS1) 和肝细胞核因子 4a 反义 RNA 1 (HNF4A-AS1) 在内的长链非编码 RNA (lncRNA) 对下游转录因子 (TF) 和细胞色素 P450 酶 (CYP) 表达的影响已得到很好的研究,但甲基转移酶样 3 (METTL3) 对这两种 lncRNA 的上游调节仍未得到探索。本研究揭示了 METTL3 通过影响 HepG2 和 Huh7 细胞中 HNF1A-AS1 和 HNF4A-AS1 的稳定性,参与 lncRNA-TF-CYP 表达的调节。